首页 | 本学科首页   官方微博 | 高级检索  
检索        

雄激素受体在前列腺增生和前列腺癌组织中的表达
引用本文:王荣海,杨明山.雄激素受体在前列腺增生和前列腺癌组织中的表达[J].山东大学学报(医学版),2008,46(5):506-509.
作者姓名:王荣海  杨明山
作者单位:1. 山东大学医学院,济南,250012
2. 山东省肿瘤医院泌尿外科,济南,250117
摘    要:目的探讨雄激素受体(AR)在前列腺特异性抗原高的良性前列腺增生(BPH)组织和前列腺癌(PCa)组织中表达的意义。 方法采用免疫组化和RT-PCR法研究AR在32例前列腺特异性抗原(PSA)≥10ng/mL的BPH(简称高PSA组)、40例PCa组织中表达的情况;32例PSA<10ng/mL的BPH(简称低PSA组)组织为对照组。 结果低PSA组、高PSA组、PCa组AR表达的阳性率分别为84.38%、93.75%、65.00%,相互比较,差异均有统计学意义(P<0.05)。AR在高PSA组上皮、间质组织中的表达高于低PSA组和PCa组织(P<0.05)。高分化癌、中分化癌、低分化癌的AR表达的阳性率分别为66.67%、55.56%、30.00%,高、中分化癌的AR表达的阳性率比低分化癌高(P<0.05)。早期前列腺癌的AR表达阳性率(68.75%)比晚期前列腺癌(41.67%)高(P<0.05)。早期前列腺癌的AR mRNA表达量比晚期前列腺癌高(P<0.05);高、中分化癌的AR mRNA表达量比低分化癌高(P<0.05)。 结论AR在高PSA组前列腺增生组织中表达增高,提示其在前列腺增生中的过表达可能是PSA增高的又一因素。AR的表达与肿瘤分级、分期相关。

关 键 词:前列腺肿瘤  雄激素受体  前列腺特异性抗原  前列腺增生
文章编号:1671-7554(2008)05-0506-04
收稿时间:2007-11-08
修稿时间:2007年11月8日

Expressions of androgen receptor in benign prostatic hyperplasia with High PSA value and prostatic cancer
WANG Rong-hai,YANG Ming-shan.Expressions of androgen receptor in benign prostatic hyperplasia with High PSA value and prostatic cancer[J].Journal of Shandong University:Health Sciences,2008,46(5):506-509.
Authors:WANG Rong-hai  YANG Ming-shan
Institution:1. School of Medicine, Shandong University, Jinan 250012, China; 2. Department of Urology, Shandong Tumor Hospital, Jinan 250117, China
Abstract:Objective To investigate the expressions of androgen receptor (AR) in benign prostatic hyperplasia (BPH) with high PSA value and prostatic cancer(PCa) tissues and its clinical significance. MethodsAR expressions were determined in 32 human prostatic hyperplasia tissue specimens(PSA≥10ng/mL group)(the high PSA group) and 40 prostatic cancer tissues by immunohistochemical and RT PCR methods. 32 human prostatic hyperplasia tissue specimens(PSA<10ng/mL group)(the low PSA group) served as the control group. Results The positive staining rates of AR in the high PSA group, the low PSA group and the PCa group were respectively 93.75%, 84.38% and 65.00%(P<0.05). Positive expressions of AR were much higher in epithelial and mysenchymal tissues of the high PSA group than in the low PSA group and the PCa group(P<0.05). The AR expression was significantly higher in well (66.67%) or moderately (55.56%) differentiated adenocarcinoma than that in poorly differentiated tumors (30.00%)(P<0.05), and it was higher in tumors at early stages (68.75%) than in tumors at advanced stages (41.67%)(P<0.05). AR mRNA expression was also determined by RT PCR, and it was much higher in epithelial and mysenchymal tissues of the high PSA group than in prostatic tissues of the low PSA group (P<0.05). Also it was significantly higher in well or moderately differentiated adenocarcinoma than in poorly differentiated tumors (P<0.05) and higher in tumors at early stages than in tumors at advanced stage (P<0.05). ConclusionsAR is high in the high BPH with PSA group, indicating AR plays an important role in the regulation of PSA of prostatic tissues and therefore AR might be a causative factor in high PSA value. The expression of AR is related to tumor grades or stages.
Keywords:Prostatic hyperplasia  Prostatic neoplasms  Androgen receptor  Prostate-specific antigen
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《山东大学学报(医学版)》浏览原始摘要信息
点击此处可从《山东大学学报(医学版)》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号